Key points are not available for this paper at this time.
Introduction Following the INPULSIS and ASCEND studies, leading to the first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents for a targeted effective and better tolerated therapy able to improve the natural history of the disease.
Sofia et al. (Fri,) studied this question.